(2020) demonstrated that targeting CD109 by siRNA or CRISPR/Cas9 could inhibit cervical cancers’ tumorigenic and aggressive properties by inactivating the CD109/EGFR/STAT3 axis in vitro and in vivo [161]. Here, STAT3 is linked to cervical cancer.